Menu
Microsoft strongly encourages users to switch to a different browser than Internet Explorer as it no longer meets modern web and security standards. Therefore we cannot guarantee that our site fully works in Internet Explorer. You can use Chrome or Firefox instead.
Price
Target price
€1.10

€1.10

-3.740%
-0.0422
-3.740%
€2.38
 
20.06.25 / Tradegate WKN: A1C3EQ / Symbol: PACB / Name: PacBio / Stock / Healthcare Equipment & Supplies / Small Cap /
Please give a prediction to see the opinions of the community
sharewise uses Wisdom of crowds to gather information regarding a security. Wisdom of crowds works best if you do not see the predictions of others before giving your estimate. Please click one button to see how the community sees this security.
JavaScript chart by amCharts 3.21.15
JavaScript chart by amCharts 3.21.15
JavaScript chart by amCharts 3.21.15JS chart by amCharts
Select a timeframe to show chart data
From: to:
Zoom:
Loading data...

Pacific Biosciences of California Inc. Stock

Pacific Biosciences of California Inc. took a tumble today and lost -€0.042 (-3.740%).
Based on 3 Buy predictions and 2 Sell predictions the sentiment towards Pacific Biosciences of California Inc. is rather balanced.
As a result the target price of 2 € shows a very positive potential of 82.05% compared to the current price of 1.1 € for Pacific Biosciences of California Inc..
For the coming years our community has positive and negative things to say abot the Pacific Biosciences of California Inc. stock. Criterium "Worthwhile Investment for the next years" gathered the most positive votes but regarding "Worthwhile Investment for the next years" there were negative voices in the community.

Pros and Cons of Pacific Biosciences of California Inc. in the next few years

Pros
?
W********* I********* f** t** n*** y****
?
S********** s********
?
M***** P*******
Cons
?
B****
?
G***** c******* t* c**********
?
C******** o* t** e**********
Tell us your opinion to access the 'Wisdom of the Crowds'

Performance of Pacific Biosciences of California Inc. vs. its peers

Security Change(%) 1w 1m 1y YTD 3y 5y
Pacific Biosciences of California Inc. -3.740% 5.290% 22.094% -24.836% -37.792% -72.777% -65.234%
MicroVision Inc -4.530% 4.918% 0.612% 16.117% -35.833% -73.359% -24.763%
Fluidigm Corp. -1.090% 2.260% -1.093% -51.862% -47.076% -46.983% -73.090%
Cytosorbents Corp. 3.600% 11.663% 36.053% 39.166% 18.578% -42.746% -87.115%

sharewise BeanCounterBot

The analysis provided is generated by an artificial intelligence system and is provided for informational purposes only. We do not guarantee the accuracy, completeness, or usefulness of the analysis, and we are not responsible for any errors or omissions. Use of the analysis is at your own risk.
Last updated at 2024-08-01

Evaluating the financial health of PacBio (US symbol PACB), a player in the Healthcare Equipment & Supplies sector, reveals a company currently grappling with numerous challenges, specifically in profitability and cash flow management. The financial statements indicate a significant struggle to turn revenue into profit, reflected in the negative net income over the past few years. Though there's potential in its technology and operations, the financial metrics point towards an urgent need for strategic improvements.

Market Potential and Innovation: PacBio operates in a rapidly evolving industry characterized by advancements in genomic technologies. With increasing demand for personalized medicine and genome sequencing, the company is positioned within a high-growth segment. This market potential supports the future revenue generation prospects.

Strong Asset Base: The total assets on the balance sheet amount to approximately $1.75 billion, reflecting a robust infrastructure for operations. The presence of intellectual property, shown through significant intangible assets ($456 million in 2023), can provide future value through product developments and licensing opportunities.

Comments

Prediction Buy
Perf. (%) 17.03%
Target price 1.608
Change
Ends at 15.05.26

Pacific Biosciences of California, Inc. (NASDAQ: PACB) had its "overweight" rating re-affirmed by analysts at Stephens. They now have a $1.80 price target on the stock.
Ratings data for PACB provided by MarketBeat
Show more

Pacific Biosciences of California, Inc. (NASDAQ: PACB) was upgraded by analysts at StockNews.com to a "sell" rating.
Ratings data for PACB provided by MarketBeat
Show more

Prediction Buy
Perf. (%) -31.59%
Target price 2.381
Change
Ends at 14.02.26

Pacific Biosciences of California, Inc. (NASDAQ: PACB) had its "overweight" rating re-affirmed by analysts at Stephens. They now have a $2.50 price target on the stock.
Ratings data for PACB provided by MarketBeat
Show more